New Targeted Approaches Against the Ubiquitin-proteasome System in Gastrointestinal Malignancies - Medscape News

[3–5] Bortezomib (PS-341; Velcade®, Millennium Pharmaceuticals) was the first proteasome inhibitor approved for use in the clinical setting. Bortezomib is available for treatment of patients with multiple myeloma and relapsed mantle-cell lymphoma.

Aeterna Zentaris Regains North American Rights for Perifosine from Keryx - Yahoo Finance

Paul Richardson , MD, Clinical Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute commented, "On behalf of my colleagues involved worldwide in the ongoing pivotal trial comparing bortezomib and dexamethasone ...

Latest topics referred to NICE: May 2012 - Department of Health

To appraise the clinical and cost effectiveness of bortezomib within its licensed indication for induction therapy prior to high dose chemotherapy and autologous stem cell transplantation for the treatment of multiple myeloma. To appraise the clinical and ...

ZYTIGA® (abiraterone acetate) Data to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting - Stockhouse

About VELCADE ® (bortezomib) [3] VELCADE ® (bortezomib) is a first-in-class proteasome inhibitor approved in the EU for use in combination with melphalan and prednisone in previously untreated patients with multiple myeloma (i.e. the front line setting ...

Lenalidomide-based Regimens for Multiple Myeloma - Med India

Chemotherapy earlier included two medications, melphalan and prednisone. Later, other medications like thalidomide, bortezomib and lenalidomide were added to these two drugs. These newer additions were found to enhance the benefits of chemotherapy in ...

Pharmacyclics Reports Fiscal 2012 Third Quarter Financial Results and Recent Developments - Yahoo Finance

PCYC-1104-CA: A multicenter, Phase II study of ibrutinib in patients with relapsed or refractory mantle cell lymphoma, including cohorts of subjects either previously treated with bortezomib or naïve to bortezomib treatment. This trial is ...

5 Reasons To Buy Astex Pharmaceuticals - Seekingalpha.com

Preliminary results are expected in the fourth quarter. AT7519, a drug that inhibits multiple cyclin-dependent kinases, or CDKs, is in a Phase II trial in combination with bortezomib in patients with multiple myeloma. Data from this trial is expected in Q4 2012.

Aeterna Zentaris Regains North American Rights to Akt Inhibitor from Keryx - Genetic Engineering News

The multiple myeloma study, being carried out under a Special Protocol Assessment, is evaluating perifosine combined with bortezomib (Velcade®) and dexamethasone therapy in the treatment of about 400 patients with relapsed or relapsed ...

6 Best Biotech Stocks With More Upside Potential - Seekingalpha.com

The "408 trial" is a Phase I/II trial exploring TH-302 monotherapy and in combination with bortezomib in patients with multiple myeloma. The "410 trial" is a Phase 1/2 trial in combination with sunitinib in patients with renal cell carcinoma ...

New drug combination halts lung cancer spread - Private Health UK

But the results demonstrated that by bypassing Ras and using Bortezomib and Fasudil to affect GATA2, another gene associated in the metabolism of tumour growth, cancer in the lungs could be reduced by 99 per cent. Dr Julian Downward, lead author from ...